FIGURE 3.
Progression-free survival in the HP group (n = 48): 6.6 months; in the HX group (n = 44): 7.2 months, (P = 0.90). HP = trastuzumab plus cisplatin, HX = trastuzumab plus capecitabine.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.